知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

19 records (took 0.022 seconds)

    ONCOLYTIC VACCINIA VIRUS CANCER THERAPY
    2.
    发明申请
    ONCOLYTIC VACCINIA VIRUS CANCER THERAPY 审中-公开

    公开(公告)号：US20100303714A1

    公开(公告)日：2010-12-02

    申请号：US12531353

    申请日：2008-03-17

    Applicant: David Kirn

    Inventor： David Kirn

    IPC: A61K35/76 ,  A61K51/00 ,  A61P35/00

    CPC classification number: C12N15/86 ,  A61K35/768 ,  A61K38/193 ,  A61P35/00 ,  C12N2710/24132 ,  C12N2710/24143 ,  C12N2710/24171

    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject administered at least 1×108 viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.

    Abstract translation: 本发明的实施方案是包括胸苷激酶缺陷型痘苗病毒的定向方法。 所述方法包括以增加的病毒浓度施用痘苗病毒。 本发明的其它方面包括用于诱导具有肿瘤的受试者的肿瘤脉管系统的溶解或破裂的方法，包括向施用至少1×108病毒颗粒的受试者施用TK缺陷型，GM-CSF表达的，复制能力的牛痘 病毒载体足以诱导肿瘤细胞的溶解。

    Methods and Compositions Concerning Poxviruses and Cancer
    6.
    发明申请
    Methods and Compositions Concerning Poxviruses and Cancer 有权
    关于痘病毒和癌症的方法和组成

    公开(公告)号：US20090004723A1

    公开(公告)日：2009-01-01

    申请号：US11838757

    申请日：2007-08-14

    Applicant: David Kirn ,  Steve H. Thorne

    Inventor： David Kirn ,  Steve H. Thorne

    IPC: C12N7/00 ,  C12N5/06

    CPC classification number: A61K35/768 ,  A61K38/21 ,  A61K45/06 ,  A61K48/00 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/24121 ,  C12N2710/24132 ,  C12N2710/24143 ,  C12N2710/24161 ,  C12N2710/24162 ,  A61K2300/00

    Abstract: The present invention concerns methods and compositions for the treatment of cancer and cancer cells using altered poxviruses, including a vaccinia virus that has been altered to generate a more effective therapeutic agent. Such poxviruses are engineered to be attenuated or weakened in their ability to affect normal cells. In some embodiments, methods and compositions involve poxviruses that possess mutations that result in poxviruses with diminished or eliminated capability to implement an antiviral response in a host. Poxviruses with these mutations in combination with other mutations can be employed for more effective treatment of cancer.

    Abstract translation: 本发明涉及使用改变的痘病毒治疗癌症和癌细胞的方法和组合物，其包括已被改变以产生更有效治疗剂的痘苗病毒。 这种痘病毒被设计为在影响正常细胞的能力方面被减弱或削弱。 在一些实施方案中，方法和组合物涉及具有导致痘病毒的突变的痘病毒，其具有减少或消除在宿主中实施抗病毒反应的能力。 具有这些突变与其它突变组合的痘病毒可用于更有效地治疗癌症。

    Selective killing and diagnosis of p53+ neoplastic cells
    7.
    发明授权
    Selective killing and diagnosis of p53+ neoplastic cells 失效
    选择性杀伤和诊断p53 +肿瘤细胞

    公开(公告)号：US06296845B1

    公开(公告)日：2001-10-02

    申请号：US09190930

    申请日：1998-11-12

    Applicant: Adam Sampson-Johannes ,  David Kirn

    Inventor： Adam Sampson-Johannes ,  David Kirn

    IPC: A61K4800

    CPC classification number: G01N33/57484 ,  A61K35/761 ,  C12N2710/10332 ,  C12N2710/10362

    Abstract: Methods and compositions for treating and diagnosing neoplastic disease using viruses are provided. Preferably, mutant adenovirus lacking viral proteins which bind and/or inactivate p53 are administered to a patient having a neoplasm which comprises cells exhibiting p53 and lacking, or substantially devoid of mismatch repair activity. The mutant virus is able to substantially produce a replication phenotype in such neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 function. The preferential generation of a replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.

    Abstract translation: 提供了使用病毒治疗和诊断肿瘤疾病的方法和组合物。 优选地，将具有结合和/或失活p53的病毒蛋白质的突变型腺病毒施用于具有肿瘤的患者，所述肿瘤包含表现出p53并且缺乏或基本上没有错配修复活性的细胞。 突变型病毒能够在这种肿瘤细胞中基本上产生复制表型，但是在具有基本正常p53功能的非复制型非肿瘤细胞中基本上不能产生复制表型。 在肿瘤细胞中优先产生复制表型导致直接或通过在表达病毒复制表型的细胞中表达细胞毒性基因来赘瘤细胞的优先杀伤。

    ONCOLYTIC VACCINIA VIRUS CANCER THERAPY
    9.
    发明申请
    ONCOLYTIC VACCINIA VIRUS CANCER THERAPY 有权

    公开(公告)号：US20120276053A1

    公开(公告)日：2012-11-01

    申请号：US13535291

    申请日：2012-06-27

    Applicant: David Kirn

    Inventor： David Kirn

    IPC: A61K48/00 ,  A61P35/00

    CPC classification number: A61K48/0066 ,  A61K9/0019 ,  A61K35/768 ,  A61K38/191 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/208 ,  A61K45/06 ,  A61K48/00 ,  A61K48/0075 ,  A61N5/10 ,  C12N2710/24132 ,  A61K2300/00

    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×108 infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.

    Abstract translation: 本发明的实施方案是包括胸苷激酶缺陷型痘苗病毒的定向方法。 所述方法包括以增加的病毒浓度施用痘苗病毒。 本发明的其它方面包括在具有肿瘤的受试者中诱导肿瘤脉管系统的溶解或破坏的方法，包括向受试者施用至少1×108个感染性病毒颗粒的TK缺陷型，GM-CSF表达的，复制能力的牛痘 病毒载体足以诱导肿瘤细胞的溶解。

    Liposomal-viral DNA complexes for treating disease
    10.
    发明授权
    Liposomal-viral DNA complexes for treating disease 失效
    用于治疗疾病的脂质体病毒DNA复合物

    公开(公告)号：US6133243A

    公开(公告)日：2000-10-17

    申请号：US605568

    申请日：1996-02-22

    Applicant: David Kirn

    Inventor： David Kirn

    IPC: C12N15/09 ,  A61K31/00 ,  A61K38/16 ,  A61K48/00 ,  A61P35/00 ,  C12N7/00

    CPC classification number: A61K38/162 ,  A61K48/00

    Abstract: Methods and compositions for treating cancer consisting of viral DNA in association with liposomal material, the viral DNA substantially incapable of encoding a functional viral oncoprotein capable of binding to a functional tumor suppressor gene product in a neoplastic cell, and the viral DNA capable of replicating and forming infectious virus in neoplastic cells thereby killing the neoplastic cells and substantially incapable of replicating and forming infectious virus in non-neoplastic cells that have the tumor suppressor protein.

    Abstract translation: 用于治疗由与脂质体材料相关的病毒DNA组成的癌症的方法和组合物，基本上不能编码能够结合赘生细胞中的功能性肿瘤抑制基因产物的功能性病毒癌蛋白的病毒DNA，以及能够复制和 在肿瘤细胞中形成感染性病毒，从而杀死肿瘤细胞，并且在具有肿瘤抑制蛋白的非肿瘤细胞中基本上不能复制和形成感染性病毒。

Patent Agency Ranking